Pfizer Venture Investments
Pfizer Venture Investments, established in 2004, is the corporate venture capital arm of Pfizer Inc., deploying minority strategic capital into biotech companies aligned with Pfizer's therapeutic areas, particularly oncology. Recent investments span T-cell engagers, DNA damage response inhibitors, and AI-driven cancer drug discovery, complementing Pfizer's broader pipeline of 96 candidates across multiple modalities.
- Company typePublic
- Founded1849
- HeadquartersNew York, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Pfizer Venture Investments does
Pfizer Venture Investments is the corporate venture capital arm of Pfizer Inc., established in 2004 to deploy strategic capital into biotechnology companies operating in therapeutic areas of current or future interest to Pfizer. The arm pursues minority equity positions and co-investment alongside specialist life-sciences VCs (e.g., Taiho Ventures, Arkin Bio Capital, Polaris Partners), with recent activity concentrated in oncology modalities including T-cell engagers (Crossbow Therapeutics, $77M Series B, March 2026), DNA damage response inhibitors (Artios, $115M Series D, November 2025), and AI-driven cancer drug discovery (Iambic, $100M, November 2025). Pfizer Venture Investments is operated from Pfizer's New York headquarters at 66 Hudson Boulevard East and functions as one component of Pfizer's broader external innovation strategy.
Pfizer Inc., founded in 1849 and listed on NYSE under ticker PFE, is one of the world's largest biopharmaceutical companies with a multi-modal technology platform spanning small molecules, biologics, antibody-drug conjugates (ADCs), bispecific antibodies, mRNA, and vaccines. As of May 5, 2026, the company maintains a pipeline of 96 candidates across Phase 1 (35), Phase 2 (25), Phase 3 (31), and Registration (5), spanning oncology, inflammation & immunology, vaccines, and internal medicine. The oncology research unit is organized into four pillars — Tumor Cell Biology, Bioconjugates Discovery and Development, Precision Medicine, and Integrative Biology and Biochemistry — supporting a marketed portfolio that includes IBRANCE (palbociclib), PADCEV (enfortumab vedotin), TUKYSA (tucatinib), ELREXFIO (elranatamab), and the vaccine ABRYSVO. The Seagen acquisition brought the ADC platform and PADCEV into the portfolio, with co-development partner Astellas Pharma advancing label expansion into muscle-invasive bladder cancer.
Pfizer generates revenue primarily through pharmaceutical product sales across branded prescription medicines, vaccines, and biologics, supplemented by licensing and royalty arrangements (e.g., the BioNTech COVID-19 vaccine collaboration, the Valneva Lyme disease vaccine partnership). Go-to-market combines enterprise field sales to healthcare providers and institutions via the PfizerPro portal, direct-to-consumer engagement through PfizerForAll, traditional pharmacy distribution, and the patient assistance platform Pfizer RxPathways serving uninsured and underinsured patients. Geographic reach spans 10+ major markets including the US, UK, Germany, France, Japan, China, India, Brazil, Australia, and Canada, with the Accord for a Healthier World program extending access on a not-for-profit basis to 1.2 billion people across 45 lower-income countries. The company employs 10,000+ staff globally and is led by managing directors Dan Littman and Helen Hobbs within the venture investments function.
Pfizer Venture Investments firmographics
Firmographics- Name
- Pfizer Venture Investments
- Legal name
- Pfizer Inc.
- Website
- https://pfizer.com
- Company type
- Public
- Founded year
- 1849
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Pfizer Venture Investments, established in 2004, is the corporate venture capital arm of Pfizer Inc., deploying minority strategic capital into biotech companies aligned with Pfizer's therapeutic areas, particularly oncology. Recent investments span T-cell engagers, DNA damage response inhibitors, and AI-driven cancer drug discovery, complementing Pfizer's broader pipeline of 96 candidates across multiple modalities.
- Ownership category
- akta.pro rank
Pfizer Venture Investments industry classification
Industry- Product category
- Corporate Venture Capital
- NAICS
- All Other Financial Investment Activities (52399)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
Keywords
Where Pfizer Venture Investments is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pfizer Venture Investments business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D
Revenue model
- Pharmaceutical Product Sales: Revenue generated from sales of branded prescription medicines, vaccines, and biologics across therapeutic areas including oncology, inflammation & immunology, vaccines, and internal medicine. Products are sold through multiple channels including healthcare providers, pharmacies, and directly to consumers.
- Licensing and Royalty Revenue: Revenue from licensing proprietary technologies, drug compounds, and intellectual property to other pharmaceutical companies. Also includes royalty arrangements from approved products.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Pfizer Venture Investments product offering
Product offeringCore offering
Pfizer Venture Investments is the corporate venture capital arm of Pfizer Inc., founded in 2004. It provides strategic equity capital and venture investment funding to early-stage and growth-stage biotechnology companies whose therapeutic focus areas align with Pfizer's strategic interests, particularly in oncology, vaccines, inflammation and immunology, and internal medicine. The firm participates as an investor in private financing rounds alongside other venture capital and strategic partners, targeting companies developing novel modalities such as antibody-drug conjugates, T-cell engagers, DDR inhibitors, and AI-driven drug discovery platforms.
Product overview
Pfizer is a global biopharmaceutical company with a diversified portfolio spanning four therapeutic areas: Internal Medicine (cardiovascular, metabolic, kidney diseases), Inflammation & Immunology, Vaccines, and Oncology. The company maintains an active product pipeline of 96 candidates as of May 2026, including small molecules, biologics (antibody-drug conjugates, bispecific antibodies), and vaccines. Key marketed products include IBRANCE (palbociclib), PADCEV (enfortumab vedotin), TUKYSA (tucatinib), and ELREXFIO (elranatamab) in oncology; HYMPAVZI (marstacimab) for hemophilia; and ABRYSVO for RSV. The company serves patients through programs like Pfizer RxPathways and PfizerForAll, and healthcare professionals through PfizerPro.
Differentiator
Problem solved
Functional benefit
Products and services
- Pfizer Ventures Strategic Equity Investment Program
Quantifiable outcome
- Pfizer RxPathways has connected millions of uninsured and underinsured patients to medications
- +2 more outcomes
Companies that use Pfizer Venture Investments
Customer profileNamed customers12 records
Segments4 records
Ideal customer profiles2 records
Pfizer Venture Investments technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pfizer Venture Investments partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- American Cancer SocietycorePfizer and American Cancer Society launched three-year initiative 'Change the Odds: Uniting to Improve Cancer Outcomes' addressing cancer disparities and improving health outcomes in medically underrepresented US communities.
- AVON Foundation for WomencorePfizer established grants program with AVON Foundation supporting people living with metastatic breast cancer. In 2015, Avon and Pfizer each contributed $500,000 in grants awarded to 23 nonprofit organizations.
- Union for International Cancer Control (UICC)corePfizer and UICC partnered on first-of-its-kind initiative to address challenges facing metastatic breast cancer patients. $760,000 in grants awarded to 20 organizations from 18 countries under SPARC MBC Challenge program.
- Cancer Support Community / The Leukemia & Lymphoma SocietyminorCollaboration with Chronic Myeloid Leukemia Patient Experience Registry to identify and understand psychosocial and emotional needs of CML patients.
- ASCO/Conquer Cancer FoundationminorPfizer supported CancerLinQ initiative, a health IT platform designed to improve quality and value of cancer care through real-world data analysis.
- Susan G. KomenminorPfizer supported Komen Disparities initiative to reduce difference in breast cancer outcomes between African-American and Caucasian women in the US.
- PharmAccessminorGlobal Health Fellows partnership supporting PharmAccess in Zanzibar and Tanzania to implement public health insurance programs reaching at-risk populations.
- North Star AllianceminorGlobal Health Fellows partnership supporting mobile health clinics in Kenya through skills-based volunteering program.
- Health BuildersminorGlobal Health Fellows partnership supporting health systems strengthening in Rwanda.
- Infectious Diseases Institute (Uganda)minorGlobal Health Fellows partnership supporting HIV/AIDS care and treatment programs in Uganda.
- Save the ChildrenminorGlobal Health Fellows virtual partnership supporting child health programs globally.
- IFPW FoundationminorStrategic Training Executive Program (STEP 2.0) partnership providing supply chain training to healthcare professionals across Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, India, Pakistan, and Southeast Asia.
- BioNTechcoreCollaboration with BioNTech on COVID-19 vaccine development, contributing to global pandemic response.
- ValnevaminorCollaboration on Lyme Disease Vaccine Candidate (PF-07307405) development.
- Astellas PharmacoreCo-development agreement with Astellas for PADCEV (enfortumab vedotin) in muscle-invasive bladder cancer (EV-303, EV-304 trials).
- Seagen (Pfizer acquisition)corePfizer acquired Seagen to strengthen oncology portfolio, gaining ADC technology platform and approved medicines including PADCEV.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Pfizer Venture Investments competitors and assessment
Company assessmentDirect peers
- Novartis Venture Fund: Corporate venture capital arm of Novartis investing in early-stage biotech with strategic interest to the parent. Directly comparable as a pharma CVC with therapeutic-area alignment to oncology and emerging modalities.
- Roche Venture Fund: CVC arm of Roche with similar early-stage biotech investing focus and parent-company strategic alignment. Directly comparable in mandate, fund structure, and oncology/biologics concentration.
- Johnson & Johnson Innovation (JJDC): Johnson & Johnson's corporate venture arm investing across therapeutic areas with strategic interest to J&J. Comparable as a diversified pharma CVC with similar hold periods and strategic-exit orientation.
- Merck Global Health Innovation Fund (GHIF): CVC arm of Merck & Co. investing in health-tech and biotech adjacencies. Comparable as a major-pharma CVC with strategic alignment to the parent's therapeutic and digital health priorities.
- Sanofi Ventures: Sanofi's corporate venture fund targeting early-stage biotech and digital health aligned with Sanofi's therapeutic areas. Directly comparable in mandate and minority-stake strategy.
- Eli Lilly (Strategic Investment / Lilly Ventures activity): Eli Lilly participates as a strategic investor in biotech rounds (e.g., as an existing investor in Crossbow alongside Pfizer Ventures). Comparable as a peer pharma CVC making selective minority biotech investments.
- Amgen Ventures: CVC arm of Amgen investing in therapeutics, biomanufacturing, and digital health. Comparable as a biotech-major CVC with strategic-exit mandate.
- AbbVie Ventures: AbbVie's corporate venture fund focusing on early-stage biotech in oncology, immunology, and neuroscience. Comparable as a major-pharma CVC with strategic alignment to a focused therapeutic portfolio.
- Takeda Ventures: Corporate venture arm of Takeda investing in early-stage therapeutics. Comparable as a global pharma CVC with minority-investment strategy in biotech.
- Bayer Leaps (Leaps by Bayer): Bayer's CVC/impact-investing vehicle focused on biotech and health-tech with breakthrough potential. Comparable as a major-pharma CVC with strategic capital deployment mandate.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights4 records
Customer concentration
Pfizer Venture Investments social profiles
Digital presencePfizer Venture Investments financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pfizer Venture Investments leadership team
Management profileNumber of profiles
Profiles2 records
Pfizer Venture Investments funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pfizer Venture Investments M&A and investment
M&A and investmentM&A
Investments205 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pfizer Venture Investments
What does Pfizer Venture Investments do?
Pfizer Venture Investments is the corporate venture capital arm of Pfizer Inc., founded in 2004. It provides strategic equity capital and venture investment funding to early-stage and growth-stage biotechnology companies whose therapeutic focus areas align with Pfizer's strategic interests, particularly in oncology, vaccines, inflammation and immunology, and internal medicine. The firm participates as an investor in private financing rounds alongside other venture capital and strategic partners, targeting companies developing novel modalities such as antibody-drug conjugates, T-cell engagers, DDR inhibitors, and AI-driven drug discovery platforms.
Is Pfizer Venture Investments a public or private company?
Pfizer Venture Investments is a public company. It is classified as corporate owned and is currently operating.
When was Pfizer Venture Investments founded?
Pfizer Venture Investments was founded in 1849. It employs 5,001 to 10,000 people.
Where is Pfizer Venture Investments based?
Pfizer Venture Investments is headquartered in New York, United States, in the North America region.
How does Pfizer Venture Investments make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Royalty Revenue.
Who are Pfizer Venture Investments's main competitors?
Direct peers on record are Novartis Venture Fund, Roche Venture Fund, Johnson & Johnson Innovation (JJDC), Merck Global Health Innovation Fund (GHIF), Sanofi Ventures, Eli Lilly (Strategic Investment / Lilly Ventures activity), Amgen Ventures, AbbVie Ventures, Takeda Ventures and Bayer Leaps (Leaps by Bayer).
Does Pfizer Venture Investments have an API?
No public API is recorded for Pfizer Venture Investments.
What industry is Pfizer Venture Investments in?
Pfizer Venture Investments's product category is Corporate Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52399 and its SIC code is 6282.